Price Action To Observe: A Reversal for Cynapsus Therapeutics Inc Is Not Near. The Stock Reaches All Time High Today

Price Action To Observe: A Reversal for Cynapsus Therapeutics Inc Is Not Near. The Stock Reaches All Time High Today

The stock of Cynapsus Therapeutics Inc (NASDAQ:CYNA) reached all time high today, Oct, 5 and still has $59.66 target or 48.00% above today’s $40.31 share price. This indicates more upside for the $530.24 million company. This technical setup was reported by If the $59.66 PT is reached, the company will be worth $254.52M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 20,166 shares traded hands. Cynapsus Therapeutics Inc (NASDAQ:CYNA) has risen 198.45% since March 2, 2016 and is uptrending. It has outperformed by 190.19% the S&P500.

Analysts await Cynapsus Therapeutics Inc (NASDAQ:CYNA) to report earnings on November, 10. They expect $-0.77 earnings per share, down 527.78% or $0.95 from last year’s $0.18 per share. After $-0.83 actual earnings per share reported by Cynapsus Therapeutics Inc for the previous quarter, Wall Street now forecasts -7.23% EPS growth.

Cynapsus Therapeutics Inc (NASDAQ:CYNA) Ratings Coverage

Out of 2 analysts covering Cynapsus Therapeutics Inc. (NASDAQ:CYNA), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cynapsus Therapeutics Inc. has been the topic of 2 analyst reports since April 12, 2016 according to StockzIntelligence Inc. The firm has “Buy” rating given on Wednesday, June 15 by Janney Capital. The firm has “Outperform” rating by BMO Capital Markets given on Tuesday, April 12.

According to Zacks Investment Research, “Cynapsus Therapeutics, Inc. is a specialty pharmaceutical company engaged in developing a drug used to treat the symptoms of Parkinson’s disease. The Company’s drug candidate, APL-130277, is a reformulation of apomorphine, which is approved in an injection formulation to rescue patients from off episodes. Cynapsus Therapeutics Inc. is headquartered in Toronto, Canada.”

More notable recent Cynapsus Therapeutics Inc (NASDAQ:CYNA) news were published by: which released: “Cynapsus Therapeutics Inc. Acquisition May Not Be in the Best Interests of …” on September 08, 2016, also with their article: “Why Cynapsus Therapeutics Inc (CYNA), Hewlett Packard Enterprise Co (HPE) and …” published on September 01, 2016, published: “CYNAPSUS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation …” on September 06, 2016. More interesting news about Cynapsus Therapeutics Inc (NASDAQ:CYNA) were released by: and their article: “/quotes/zigman/3870025/realtime” published on June 19, 2015 as well as‘s news article titled: “ISS Recommends Cynapsus Therapeutics Securityholders Vote for the Plan of …” with publication date: September 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment